Beranda › Kanker Prostat › California › Irvine
Uji klinis Kanker Prostat di Irvine, CA
14 studi untuk Kanker Prostat mencari peserta di lokasi sekitar Irvine (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Menerima pesertaFase 3
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- City of Hope at Irvine Lennar, Irvine
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Menerima pesertaFase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Menerima pesertaFase 3
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120), Irvine
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Menerima pesertaFase 3
- UCLA Hematology/Oncology - Irvine, Irvine
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Menerima pesertaFase 3
- City of Hope Lennar Foundation Cancer Center ( Site 0059), Irvine
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaFase 1
- Hoag Memorial Hospital Presbyterian, Irvine
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Menerima pesertaFase 3
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Menerima peserta
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer
Menerima peserta
- City of Hope at Irvine Lennar, Irvine
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Menerima pesertaFase 3
- Research Site, Irvine
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Menerima pesertaFase 3
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- City of Hope at Irvine Lennar, Irvine
- Kaiser Permanente-Irvine, Irvine
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Menerima pesertaFase 2
- City of Hope at Irvine Lennar, Irvine
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Irvine
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Menerima pesertaFase 2
- Hoag Memorial Hospital Presbyterian, Irvine
Uji klinis Kanker Prostat di kota lain
- New York City, NY103 studi
- Houston, TX76 studi
- Los Angeles, CA61 studi
- Boston, MA59 studi
- St. Louis, MO46 studi
- Chicago, IL45 studi
- San Francisco, CA45 studi
- Philadelphia, PA44 studi
- Baltimore, MD43 studi
- Nashville, TN43 studi
- Seattle, WA42 studi
- Washington, DC38 studi
Studi lain di Irvine
- Kanker Paru Non-Sel Kecil25 studi
- Kanker Payudara23 studi
- Kanker (semua jenis)17 studi
- Kanker Metastatik16 studi
- Kanker Paru15 studi
- Mieloma Multipel14 studi
- Kanker Ovarium12 studi
- Karsinoma Sel Skuamosa Kepala dan Leher11 studi
- Kanker Kandung Kemih11 studi
- Penyakit Alzheimer11 studi
- Kanker Kolorektal10 studi
- Kanker Pankreas10 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.